H6PDH regulates splenic pDC survival in the steady but not inflammatory state. (A) The frequency of pDCs (as a percentage of live gated cells) in spleen and lymph nodes (LN) of H6pdh^+/+ versus H6pdh^−/− mice. (B) The frequency of pDCs (as a percentage of live gated cells) in spleen and lymph nodes of (H6pdh^+/+→H6pdh^+/+) versus (H6pdh^−/−→H6pdh^+/+) BM chimeras 12 weeks after reconstitution. (C) H6pdh^+/+ (CD45.1):H6pdh^−/− (CD45.2)→H6pdh^+/+ (CD45.1) mixed BM chimeras were evaluated 12 to 16 weeks after hematopoietic reconstitution and 24 hours after treatment with intraperitoneal PBS or CpG 1826. (Left) Representative contour plots showing plasmacytoid dendritic cell antigen-1 (PDCA-1) and sialic acid binding immunoglobulin-like lectin H (SiglecH) staining in a pregated B220⁺ splenocyte population. (Middle) Representative flow cytometric histograms showing CD45.1 staining in gated B220⁺PDCA-1⁺SiglecH⁺ cells. (Right) Summary of pooled data showing percentage of pDCs derived from H6pdh^−/− (CD45.2) or H6pdh^+/+ (CD45.1) BM. Data derived from 3 independent experiments.